N one more pivotal phase three study in patients ineligible for cytotoxic therapy
Chemexpress N one more pivotal phase 3 study in individuals ineligible for cytotoxic therapy, the combination of idelalisib plus rituximab proved superior to rituximab alone in relapsed CLL. From the 220…